Related Experiment Video
Updated: Jul 19, 2025

Deferred Growth Inhibition Assay to Quantify the Effect of Bacteria-derived Antimicrobials on Competition
Published on: September 3, 2016
In vitro effects of deferoxamine on antibiotic susceptibility in Gram-negative bacteria
1Department of Medical Microbiology, Faculty of Medicine, Gaziantep University, Turkey.
Background:
Iron is a vital element for the growth of bacteria. Bacteria use several strategies to scavenge iron, such as siderophores, which are thought to be important virulence components. The mammalian host uses various iron-binding substances to make iron unavailable for bacterial uptake. Deferoxamine (DFO) is a semi-synthetic iron chelator that has been licensed for medical use. Iron chelators like DFO may provide an alternative therapeutic technique for treating Gram-negative bacteria infections, which frequently display multidrug resistance.
Objectives:
We assumed that iron deprivation or interactions with the cell membrane caused by DFO or increased siderophore synthesis may cause the inhibition or inactivation of proteins and enzymes necessary for critical processes in bacteria. Additionally, we proposed that these bacterial alterations might be the origin of synergistic interactions between DFO and several antibiotics.
Material And Methods:
To test this hypothesis, we used disc diffusion, broth microdilution and checkerboard synergy testing methods on combinations of DFO with ceftriaxone, cefepime, meropenem, amikacin, levofloxacin, and tigecycline, respectively, in a total of 55 isolates (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Proteus mirabilis strains - 11 isolates for each genus).
Results:
No synergistic or antagonistic interactions were observed between DFO and the tested antibiotics in the E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii isolates, while the addition of DFO significantly increased the inhibition zone diameters of cefepime, amikacin, meropenem, tigecycline, and levofloxacin in P. mirabilis isolates. According to the checkerboard synergy results, a synergistic interaction was found between DFO and tigecycline, cefepime and amikacin for P. mirabilis isolates.
Conclusions:
Among the investigated bacteria, a synergy between antibiotics and DFO was only discovered against P. mirabilis. We do not believe that this entirely disproves our hypothesis, though. The production of siderophores triggered by the increased metabolic activity of actively proliferating bacteria at the infection site may provide better results. Therefore, expanding these investigations and developing infection models through animal testing would be advantageous.
Insights
Deferoxamine (DFO) showed synergistic effects with certain antibiotics only against Proteus mirabilis infections. Further research, including animal models, is recommended to explore DFO
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Iron is essential for bacterial growth, and bacteria employ strategies like siderophores to acquire it.
- The host limits iron availability to bacteria, while iron chelators like Deferoxamine (DFO) may offer therapeutic potential against multidrug-resistant Gram-negative bacteria.
Purpose of the Study:
- To investigate if iron deprivation or cell membrane interactions caused by DFO, or increased siderophore synthesis, inhibit bacterial growth.
- To determine if these bacterial alterations lead to synergistic interactions between DFO and antibiotics.
Main Methods:
- Tested combinations of DFO with six antibiotics (ceftriaxone, cefepime, meropenem, amikacin, levofloxacin, tigecycline) against 55 bacterial isolates.
- Employed disc diffusion, broth microdilution, and checkerboard synergy testing methods.
- Included isolates from Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Proteus mirabilis.
Main Results:
- No synergy or antagonism was observed between DFO and antibiotics in E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii.
- DFO significantly enhanced the efficacy of cefepime, amikacin, meropenem, tigecycline, and levofloxacin against P. mirabilis.
- Checkerboard synergy testing confirmed synergistic interactions between DFO and tigecycline, cefepime, and amikacin specifically for P. mirabilis.
Conclusions:
- Antibiotic synergy with DFO was exclusively observed against Proteus mirabilis.
- The hypothesis is not entirely disproven; increased siderophore production in actively growing bacteria might yield different results.
- Further investigation using animal infection models is recommended to validate these findings.
More Related Videos
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Antimicrobial Effectiveness
Antibiotic Selection
Development of Antibiotic Resistance